N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is
widely prescribed for patients with chronic obstructive lung disease (COPD), particularly for
those who have accompanying symptoms of chronic cough and sputum production. Compared to
placebo, high-dose NAC will improve Saint George Respiratory Questionnaire scores in patients
with COPD and chronic bronchitis.
Phase:
N/A
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute